Class / Patent application number | Description | Number of patent applications / Date published |
514211120 | Ring nitrogen is shared by plural cyclos of the tricyclo ring system | 8 |
20080306042 | Triazole Derivatives - Novel triazole derivatives are inhibitors of TGF-beta receptor I kinase, and can be employed, inter alia, for the treatment of tumours. | 12-11-2008 |
20090215743 | Tricyclic benzazepine derivatives and their use - The present application relates to novel tricyclic benzazepine derivatives, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for producing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular disorders, especially of dyslipidaemias, arteriosclerosis, restenosis and ischaemias. | 08-27-2009 |
20100273774 | INDOLYMALEIMIDE DERIVATIVES - A compound of formula (I), wherein R, R | 10-28-2010 |
20130116238 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS - Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention. | 05-09-2013 |
20140171412 | TRICYCLIC COMPOUNDS - The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; | 06-19-2014 |
20140221350 | Cyclohexyl-4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulenes as V1a antagonists - The present invention provides 4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulenes, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior. | 08-07-2014 |
20160024112 | CHEMICAL ENTITIES - Provided are chemical entities selected from compounds of formula (I), wherein R | 01-28-2016 |
20160106731 | TRICYCLIC INDOLE MCL-1 INHIBITORS AND USES THEREOF - The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein. | 04-21-2016 |